Rituximab: Clinical development and future directions

Expert Opinion on Biological Therapy

Volumn 2, Issue 1, 2002, Pages 97-110

  Cheson, Bruce D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody; CD20; CLL; Lymphoma; Monoclonal; Rituximab

Indexed keywords

ALEMTUZUMAB; APOLIZUMAB; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; ONCOLYM; PREDNISONE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

CANCER CLASSIFICATION; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOKINE RELEASE; DOSE RESPONSE; DRUG INDICATION; DRUG TOLERABILITY; FEVER; HUMAN; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; REVIEW; ANIMAL; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS;

EID: 0035989710     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.1.97     Document Type: Review

References (107)

1. Cancer statistics, 2001
2. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
3. Chemokine upregulation in response to rituximab in B-cell non-Hodgkin's lymphoma
4. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
5. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
6. Rituximab inactivates signal transducer and activator of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bcl-2 and sensitization to cytotoxic drugs
7. Responders to rituximab show continued tumor regression over time and a progression-free survival that correlates with response classification
8. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
9. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
10. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
11. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
12. IDEC-C2B8: Results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
13. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
14. Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
15. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
16. A UK multicentre Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
17. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a Phase II trial of rituximab
18. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patents with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
19. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma
20. Peripheral blood B-cell recovery in patients with non-Hodgkin's lymphoma treated with rituximab does not correlate with onset of disease progression
21. Rituximab: Sustained remissions in patients with relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
22. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma
23. Intralesional rituximab for cutaneous B-cell lymphoma
24. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
25. Final report on the safety and efficacy of retreatment with rituximab for patients with non-Hodgkin's lymphoma
26. Re-treatment of relapsed indolent B-cell lymphoma with rituximab
27. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)
28. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
29. Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: Preliminary results from CALGB 9712
30. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association between increased infusion-related side effects and rapid blood tumor clearance
31. Tumor lysis syndrome as a rare complication of fludarabine therapy in chronic lymphocytic leukemia
32. Peripheral T-cell lymphoma after anti-CD20 antibody therapy
33. Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma
34. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab
35. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients
36. Toxicity and efficacy of the anti-CD20 antibody rituximab (Rituxan) in patients with B-cell chronic lymphocytic leukemia: A Phase I/II study
37. European Phase II study of rituximab (Chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
38. Rituximab dose-escalation trial in chronic lymphocytic leukemia
39. Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukemia patients
40. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evan's syndrome
41. Rituximab therapy in previously treated Waldenström's macroglobulinemia: Preliminary evidence of activity
42. Rituximab is an active agent in Waldenstrom's macroglobulinemia (WM)
43. Rituximab in the treatment of gastrointestinal mucosa-associated lymphoid tissue lymphoma
44. Pilot study of rituximab in refractory or relapsed hairy cell leukemia
45. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter Phase II study
46. Rituximab in cutaneous B-cell lymphoma: A report of two cases
47. Primary cutaneous large B-cell lymphoma of the legs: A distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab)
48. Activity of rituximab in primary central nervous system lymphoma (PCNSL)
49. Treatment of patients with mantle-cell and aggressive B-cell non-Hodgkin's lymphoma using the monoclonal anti-CD20 antibody rituximab: Evaluation of safety and response
50. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders
51. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
52. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
53. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: A report of three cases
54. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant
55. Rituximab is active in lymphocyte predominant Hodgkin's disease
56. Monoclonal anti-CD20 antibody rituximab for treatment of CD20-positive Hodgkin's lymphoma: The German experience
57. A pilot study of rituximab in patients with relapsed Hodgkin's disease of classical type
58. Phase II study of rituximab in previously treated patients with multiple myeloma: Progress report
59. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma
60. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
61. In vivo purging with rituximab during stem cell transplantation for indolent lymphoma
62. In vivo purging with rituximab prior to stem cell collection is associated with persistent molecular evidence of t(14; 18) that often disappears post transplant in patients with follicular lymphoma
63. Efficiency of in vivo purging with rituximab followed by high-dose therapy with autologous peripheral blood stem cell transplantation in B-cell non-Hodgkin's lymphomas: A single institution study
64. Rituximab for the treatment of fludarabine (FAMP)-associated autoimmune thrombocytopenia in chronic lymphocytic leukemia (CLL): Report of three cases from a single institution
65. Response of chronic relapsing ITP of 10 years duration
66. A pilot study of anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenic purpura
67. Rituximab in the treatment of autoimmune hemolytic anemia
68. Rituximab, cyclophosphamide and decadron combination is highly effective in auto-immune hemolytic anemia associated with chronic lymphocytic leukemia
69. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia
70. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
71. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
72. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma
73. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL
74. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas
75. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
76. Rituximab in the treatment of refractory follicular lymphoma - Six doses are better than four
77. Upregulation of CD20 expression in chronic lymphocytic leukemia (CLL) cells by in vitro exposure to cytokines
78. Interferon-g (IFN-g) induces CD20 expression on multiple myeloma (MM) patient and healthy donor (HD) plasma cells and B-cells and augments binding of rituximab (Rituxan) to plasma cells
79. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
80. Synergistic cytotoxicity of iodine-131-anti-CD20 antibodies and chemotherapy for treatment of B-cell lymphomas
81. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis
82. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and chemotherapy
83. Clearing of cells bearing the bcl-2 (t(14:18)) translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
84. Pilot study of Rituxan in combination with fludarabine chemotherapy in patients with low-grade or follicular non-Hodgkin's lymphoma
85. Phase II study of rituximab in combination with fludarabine in patients (pts) with low-grade or follicular B-cell lymphoma
86. Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for indolent lymphoma trial
87. Molecular responses with fludarabine/mitoxantrone/ dexamethasone plus rituximab chemoimmunotherapy for stage IV indolent follicular non-Hodgkin's lymphoma
88. Combination chemo-antibody therapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL)
89. Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL)
90. Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL)
91. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
92. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
93. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized trial
94. Rituximab/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma
95. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma
96. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma
97. The curious case of the baffling biological
98. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a
99. Rituximab as a single agent and in combination with interferon alfa-2a as treatment of untreated and first-relapse follicular or other low-grade lymphomas: A randomized Phase II study
100. Multicenter study of CAMPATH-1H in patients with chronic lymphocytic leukemia refractory to fludarabine
101. Treatment of relapsed B-cell non Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: Final report on safety and efficacy
102. Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL)
103. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma
104. Final results of a randomized controlled study of the zevalin radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL
105. Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin's lymphoma
106. Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: Results of a multicenter Phase II study
107. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody